Growth driven by self-administration and increased development of biologics, says Visiongain
Becton, Dickinson & Co (BD) will be the largest player in the pre-filled syringe market through to 2022, a Visiongain report predicts.
This year BD’s pre-filled syringe and related technology revenue will reach $1.14bn, having grown at a compound annual growth rate (CAGR) of 7.0% since 2010. In the same period, the total pre-filled syringe market will grow at a CAGR of 8.5%.
Top Pre-Filled Syringe Manufacturers: Market Outlook 2012–2022, published by the London-based business information provider, says in 2011 five companies accounted for the supply of more than 90% of glass pre-filled syringes to the pharmaceutical industry: BD, Gerresheimer, Schott, MGlas and Nuova Ompi.
The autoinjector and pen injector submarket, which in 2010 accounted for 24% of the pre-filled syringe market, is similarly dominated by a small number of companies. Again BD is one of the leaders, along with Ypsomed, Owen Mumford and SHL Group.
In the past decade, there has been a rapid rise in the number of products supplied in pre-filled syringes, from a few products to nearly 100, Visiongain has found.
Self-administration of drugs, using pre-filled syringes and autoinjectors has moved beyond diabetes and growth hormones to a variety of therapeutic areas, including multiple sclerosis and rheumatoid arthritis, cancer, anaemia, haemophilia and osteoporosis. Much of the growth has been driven by the need for drug administration in the home. Another impetus has been increased development of biologic drugs.
Such growth also offers opportunities to medical device component manufacturers, notes Visiongain, especially companies making plungers, needle shields and tip caps. The three leading companies in this area, Daetwyler, West and Stelmi, control significant market share as a result of partnerships with leading drug and syringe manufacturers.